SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
WB Centrum Kompozytów
WB Centrum Kompozytów Spółka z Ograniczoną Odpowiedzialnością
WB Centrum Kompozytów Spółka z Ograniczoną Odpowiedzialnością (KRS 0000325477, NIP 6521699626) is a Polish company, headquartered in Czechowice-Dziedzice, Śląskie voivodeship. WB Centrum Kompozytów operates in: Other research and experimental development on natural sciences and engineering (PKD 72.19.Z). Industry: Research and development. The company has been listed in the National Court Register since March 11, 2009. WB Centrum Kompozytów's most recently reported net revenue was 38.9 M PLN for 2025.
Negative equity
Negative equity in 2 of 7 available reporting years.
No arrears identified in the analysed sources
No arrears or bankruptcy proceedings identified in the analysed sources.
Other activities
General codes (divisions and groups)
General codes indicate a PKD division or group without a specific subclass.
Credibility rating
36.2 / 100
Poor credibility
Insolvency risk
Moderate
Significant formal threat
Closure risk
11
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Spółka wykazuje sygnały niestabilności organizacyjnej: częste zmiany właścicieli. Może to wskazywać na podwyższone ryzyko współpracy.
Shareholder changes
18
18/17 yrs
Board changes
10
10/17 yrs
PKD changes
1
1/17 yrs
Name changes
1
1/17 yrs
Data from 17 years of registry activity.
Payment reliability score from 2019–2025
Current: E (36/100)
Trend: deteriorating (-4.6 pts/year)
Bardzo słaba wiarygodność płatnicza – współpraca handlowa wiąże się z wysokim ryzykiem braku zapłaty.
Standard limit from 2019–2025
Current: 1.1 M PLN
Safe: 191.0 K PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Founded
March 11, 2009
17 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
CZECHOWICE-DZIEDZICE
ŚLĄSKIE
Primary PKD
72.19.Z
Other research and experimental development on natural sciences and…
Share capital
19.8 M PLN
25,269 shares total
Shareholders
1
shareholder
Board
2 people
Sup. board: 3
Filed years
7 years
2019–2025 · profitable: 2/7
Registry entries
76
latest: June 18, 2026
Risk signals
Revenue
38.9 M PLN
2025
Net profit
814.6 K PLN
2025
Assets
45.5 M PLN
2025
Equity
-4.3 M PLN
2025
EBITDA
6.6 M PLN
2025
Valuation
6.0 M PLN
Low confidence
Low confidence
Rate business credibility - WB Centrum Kompozytów.
No ratings

News
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase on BCX-CM-J – potentially Europe's first veterinary cell-therapy drug based on mesenchymal stem cells, for dogs with osteoarthritis. Responses to the EMA's final questions are due in May 2026; a CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. A pre-commercial biotech: it closed 2024 with a PLN 14.9m loss on zero revenue and PLN 33.6m of cash at year-end. Trigon DM maintains a buy rating with a PLN 127.2 price target.

News
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) – a pre-commercial biotech specialising in targeted protein degradation (TPD) – closed Q3 2025 with PLN 36m of cash and grants securing funding to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I, with the first patient dosed at the Barcelona Clinic Liver Cancer. CT-03, an MCL-1 degrader, is close to clinical entry. Without a new R&D partnership or share issue in 2026, the company will need additional financing.
Answers to questions about the company's activity, registered office, identifiers, financial data, capital and control.
WB Centrum Kompozytów's board has 2 members.
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
WB Centrum Kompozytów Spółka z Ograniczoną Odpowiedzialnością
Latest reporting year
2025
Available years
17
Filing entries
0
20 historical registry entries for WB Centrum Kompozytów
Board change
KA.VIII NS-REJ.KRS/34429/24/974
Change in Section 1 (basic data)
KA.VIII NS-REJ.KRS/34429/24/974/ADE
Filing documents submitted (3 documents)
Board change
KA.VIII NS-REJ.KRS/27622/25/578
Filing documents submitted (4 documents)
Competing companies or those operating in the same market segment as WB Centrum Kompozytów (in Czechowice-Dziedzice, industry: Research and development).
WARSZAWA· Research and development
Revenue 2024: 92.8 M PLN
ŁÓDŹ· Research and development
Revenue 2024: 76.1 M PLN
GLIWICE· Research and development
Revenue 2024: 75.6 M PLN
WARSZAWA· Research and development
Revenue 2025: 71.2 M PLN
MIELEC· Research and development
Revenue 2024: 37.7 M PLN
TORUŃ· Research and development
Revenue 2024: 21.5 M PLN